Inflammation and Immunology Areas of Interest
IMPORTANT: Pfizer has implemented application windows for unsolicited requests. Please click here to view the Application and Batched Review Cycles.
Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. A formal notification regarding the status of your application will be sent once a decision is reached. Pfizer support will only be extended upon the execution of a research agreement. For any questions, please send an email to ExternalResearch&[email protected].
- Abrocitinib
Atopic Dermatitis (AD)
Research areas to be considered for Pfizer support include:
- Basic and clinical research to further characterize the various endotypes and phenotypes of patients with AD and their response to AD treatments
- Non-interventional studies (including epidemiological studies) related to disease burden, costs, comorbidities, and unmet need for new AD
- Translational research regarding the role of JAK/STAT pathway in AD and other skin diseases
- Clinical research into the use of JAK-1-inhibitors in AD and other dermatologic inflammatory and non-inflammatory conditions.
- Optimization of healthcare delivery for patients with moderate-severe AD
Out of Scope:
- Use in non-dermatologic conditions
- Etrasimod
Gastroenterology
- Understand etrasimod’s mechanism of action beyond effects on lymphocyte egress
- Assess mechanistic association of S1P receptor modulation and effect on immune surveillance, including response to infection or vaccination
- For patients treated with etrasimod, exploration for optimal markers or predictors (including clinical, endoscopic, histologic, ultrasonographic, genetics and other markers) of response and to monitor disease activity changes
- Role of intestinal ultrasound in monitoring the response to treatment with etrasimod
- Assess etrasimod impact on the microbiome in UC patients
- Evaluate efficacy and safety of etrasimod in UC populations of special interest including proctitis patients, elderly, adolescents and in other colitis conditions such as microscopic colitis
- Evaluate efficacy and safety of etrasimod in UC in clinical practice assessing the effect on fatigue and sleep and other patient reported outcomes
- Elucidate the role of etrasimod in extra-intestinal manifestations of UC
- Evaluate the role of etrasimod in treatment sequencing in UC, before or after exposure to other advanced therapies and different mechanisms of action.
- Patient decision-aid to assist patients with UC eligible for advanced systemic treatment with selecting the most appropriate therapy.
Out of Scope:
- Studies that overlap with completed, ongoing and planned research.
- Use in non-gastrointestinal conditions
- Ritlecitinib
Research areas to be considered for Pfizer support include:
- Basic and clinical research to further characterize the variety of patients with alopecia areata (AA) or vitiligo and their response to AA or vitiligo treatments
- Non-interventional studies (including epidemiological studies) related to disease burden, costs, comorbidities, unmet needs and pattern of treatments for AA or vitiligo.
- Translational research regarding the role of JAK3 and TEC family kinase pathways in AA, vitiligo, or other skin diseases, as well as their modulation by therapeutic intervention.
- Clinical research to assess the impact on therapeutic efficacy of early or delayed treatment with ritlecitinib in AA or Vitiligo.
- Clinical research into the use of ritlecitinib in other skin diseases.
- Studies evaluating ritlecitinib treatment in diverse patients (ex. skin of color, adolescents…)
Out of Scope:
- Use in non-dermatologic conditions
- Ritlecitinib is only approved for patients with severe AA 12 years and older.
- Pfizer does not have any approved treatments for vitiligo.